Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response : Current Knowledge, Challenges, and Future Opportunities#277480
• A review of vaccine adjuvants in modern immunology: Mechanisms, classes, and advances in next generation vaccine design: Adjuvants vaccinaux en immunologie moderne: Mécanismes, classes et avancées dans la conception des vaccins de nouvelle generation#1149013
• Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)#908377
• A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine#272422
• Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants#836244